Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
59995-65-2
Molecular formula
C26H41BrNO4+
Molecular weight
511.5 g/mol
Drug class
Gastrointestinal antispasmodicselective calcium-channel blocker in intestinal smooth muscle
Mechanism of action
Blocks voltage-dependent calcium channels in gastrointestinal smooth-muscle cells, reducing calcium influx and preventing excessive contraction. It acts predominantly locally in the gastrointestinal tract.
Indications / reported uses
Symptomatic treatment of abdominal pain, intestinal spasm and discomfort associated with functional gastrointestinal disorders, including irritable bowel syndrome, according to local product information.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Pinaverium PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Pinaverium Permitted Daily Exposure (PDE) report (the Pinaverium PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Pinaverium Occupational Exposure Limit (OEL) report (the Pinaverium OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.